SCHEMBL3880185

SCHEMBL3880185

CC1(C)CCc2cc(C(=O)O)ccc2O1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.64
SSTR5 P35346 1/20 0.51
COXFA4 O00483 1/20 0.50
TDP1 Q9NUW8 3/20 0.48
MAPT P10636 3/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPK1 P28482 2/20 0.47
CYP2C19 P33261 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
BLM P54132 1/20 0.47
GRM1 Q13255 1/20 0.47
MEN1 O00255 1/20 0.47
CTSB P07858 1/20 0.46
PKM P14618 2/20 0.44
MGAM O43451 1/20 0.44
GAA P10253 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30195971 1.00 RXRA (0.64) RXRASSTR5COXFA4TDP1MAPT
SCHEMBL5712102 0.91 RXRA (0.55) RXRASSTR5COXFA4TDP1MAPT
SCHEMBL6210627 0.88 RXRA (0.50) RXRASSTR5COXFA4TDP1MAPT
SCHEMBL30026892 0.88 RXRA (0.50) RXRASSTR5COXFA4TDP1MAPT
SCHEMBL3782343 0.86 COXFA4 (0.49) RXRASSTR5COXFA4TDP1MAPT
SCHEMBL9850252 0.86 RXRA (0.53) RXRASSTR5COXFA4TDP1MAPT
SCHEMBL5311364 0.85 RXRA (0.49) RXRASSTR5COXFA4TDP1MAPT
SCHEMBL2812534 0.84 RXRA (0.52) RXRASSTR5TDP1MAPTALDH1A1
SCHEMBL26054454 0.84 COXFA4 (0.47) RXRASSTR5COXFA4TDP1MAPT
SCHEMBL16742142 0.84 COXFA4 (0.53) RXRASSTR5COXFA4TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150148292-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO UNIV EMORY (US) 2015-05-28 US claimed
WO-2014011540-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2014-01-16 WO claimed
US-12492177-B2 RAR-α compounds for inflammatory disease and male contraception Orphagen Pharmaceuticals, Inc. (US) 2025-12-09 US disclosed
US-20230357175-A1 RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION Orphagen Pharmaceuticals, Inc. 2023-11-09 US disclosed
US-20230357175-A1 RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION Orphagen Pharmaceuticals, Inc. 2023-11-09 US disclosed
US-20230357175-A1 RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION Orphagen Pharmaceuticals, Inc. 2023-11-09 US disclosed
CN-115335367-A RAR-alpha compounds for use in inflammatory diseases and male contraception 奥弗恩制药公司 2022-11-11 CN disclosed
EP-4077300-A1 RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION Orphagen Pharmaceuticals, Inc. (US) 2022-10-26 EP disclosed
WO-2021127250-A1 RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION Orphagen Pharmaceuticals, Inc. (US) 2021-06-24 WO disclosed
WO-2021127250-A1 RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION Orphagen Pharmaceuticals, Inc. (US) 2021-06-24 WO disclosed
US-20210070748-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC (US) 2021-03-11 US disclosed
EP-0991636-B1 SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES ALLERGAN INC (US) 2005-03-02 EP disclosed
US-6455520-B1 TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS ASTRA ZENECA AB (SE) 2002-09-24 US disclosed
EP-1115707-A1 BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-07-18 EP disclosed
EP-0991636-A1 SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES Allergan Sales, Inc. (US) 2000-04-12 EP disclosed
WO-2000018738-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-04-06 WO disclosed
US-5877207-A SKIN DISORDERS; ANTICARCINOGENIC AGENTS ALLERGAN SALES, INC. (US) 1999-03-02 US disclosed
WO-1998058922-A1 SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES ALLERGAN SALES, INC. (US) 1998-12-30 WO disclosed
EP-0435681-A1 Chroman esters of phenols and benzoic acids having retinoid-like activity ALLERGAN, INC. (US) 1991-07-03 EP disclosed
US-5006550-A Skin disorder, arthritis, wound healing agents, dry eye syndrome ALLERGAN, INC. (US) 1991-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357175-A1 RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION RARA, RARB, RARG RXRA 4/4885SSTR5 3496/4885COXFA4 2212/4885
US-20210070748-A1 INHIBITORS OF BRUTONS TYROSINE KINASE BTK, LYN, LCK RXRA 3691/4885SSTR5 4556/4885COXFA4 4806/4885
US-20150148292-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO BMP4, BMP2, BMP1 RXRA 773/4885SSTR5 3345/4885COXFA4 945/4885
US-12492177-B2 RAR-α compounds for inflammatory disease and male contraception RARA, RARB, RARG RXRA 4/4885SSTR5 3496/4885COXFA4 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.